IL1F9 Protein (AA 18-169)

Catalog No. ABIN2667525

Recombinant IL1F9 protein expressed in Escherichia coli (E. coli).

Quick Overview for IL1F9 Protein (AA 18-169) (ABIN2667525)

Target: IL1F9 (Interleukin 1 Family Member 9 (IL1F9))

Protein Type: Recombinant

Biological Activity: Active

Origin: Human

Source: Escherichia coli (E. coli)

Application: Western Blotting (WB), Immunofluorescence (IF)

Purity: >98 % , as determined by Coomassie stained SDS-PAGE and HPLC analysis.

Product Details

Protein Characteristics: AA 18-169

Endotoxin Level:

Less than 0.1 ng per μg of protein.

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Comment:

Biological activity: Measured by its ability to induce IL-8 production by human PBMCs.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: For maximum results, quick spin vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/mL. Do not vortex. It is recommended to further dilute in a buffer, such as 5 % Trehalose, and store working aliquots at -20 °C to -80 °C.

Buffer: Lyophilized, carrier-free.

Handling Advice: Avoid repeated freeze/thaw cycles.

Storage: -20 °C

Storage Comment: Unopened vial can be stored at -20°C or -70°C.

Target Details

Target: IL1F9 (Interleukin 1 Family Member 9 (IL1F9))

Alternative Name: IL-36 gamma

Background: The IL-1 family is a group of cytokines comprised of 11 membranes, including recently renamed IL-36 cytokines, IL-36 α, β and γ (previously known as IL-1F6, IL-1F8 and IL-1F9). IL-36γ signals through the IL-1 receptor family members IL-1Rrp2 and IL-1RAcP and can activate downstream MAP kinases and transfection factor NF-kB. IL-36γ is synthesized without signal peptide and the secretion pathway is unclear. It has been shown that, like other IL-36 cytokines, N-terminal processing of IL-36γ can significantly increase its biological activity. The possible processing enzymes are currently unknown. IL-36γ also plays a significant role in immune response. Low level of IL-36 receptor IL-1Rrp can be detected on bone marrow-derived dendritic cells and CD4+ T cells. IL-36γ treatment can upgulate CD80, CD86 and MHC Class II, and proinflammatory cytokine producton in dendritic cells. IL-36γ has also been implicated in airway hyperesponsiveness. Intranasal administration of recombinant IL-36γ in mice leads to epithelial cell hypertrophy, cellular infiltration, and mucus production. IL-36γ expression in the lungs of mice can be upregulated by allergic inflammation.

Molecular Weight: The 152 amino acid recombinant protein has a predicted molecular mass of approximately 17 kDa. The predicted N-terminal amino acid is Ser.